AI Article Synopsis
- Oral squamous cell carcinoma (OSCC) has high morbidity and mortality rates, and timely diagnosis is essential for better patient outcomes; however, diagnostic delays are a significant concern.
- A study with 226 OSCC patients examined demographic and socioeconomic factors contributing to these delays, finding that the average delay was 55.2 days, with a significant number of patients affected by delays over 40 days.
- Key factors linked to longer delays included older age, single marital status, lower education, and lower income, highlighting the need for targeted interventions to improve early detection and patient outcomes.
Article Abstract
Background: Oral squamous cell carcinoma (OSCC) is a prevalent malignancy with high morbidity and mortality rates. Timely diagnosis is critical for improving patient outcomes; however, diagnostic delays remain a concern. Understanding the factors that contribute to these delays is essential for developing effective interventions. This cross-sectional study aimed to investigate the demographic, socioeconomic, and clinical determinants of diagnostic delay in patients with OSCC.
Methods: This cross-sectional study included 226 patients with OSCC. Demographic data, including age, sex, marital status, education, and monthly household income, were collected. The time from symptom onset to definitive diagnosis was recorded. Stratified analysis and chi-square tests were conducted to assess the association between demographic and socioeconomic factors and diagnostic delays.
Results: The mean diagnostic delay was 55.2 days, with 61.9% of the patients experiencing delays exceeding 40 days. Older age (>50 years), single marital status, lower educational level, and lower monthly income were associated with longer diagnostic delays (p < 0.05). Delays in biopsy sample collection also correlated with increased diagnostic delay (p < 0.05).
Conclusion: Demographic and socioeconomic factors significantly influence diagnostic delays in patients with OSCC. Targeted interventions to address these disparities are crucial for improving early detection and enhancing patient outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.31557/APJCP.2024.25.11.3997 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Data-Driven Characterization of Individuals With Delayed Autism Diagnosis.
JAMA Pediatr
January 2025
Computational Health Informatics Program, Boston Children's Hospital, Boston, Massachusetts.
Association Between Diagnostic Delay and Economic and Clinical Burden in Axial Spondyloarthritis: A Multicentre Retrospective Observational Study.
Rheumatol Ther
January 2025
Rheumatology Department, Parc Taulí University Hospital. Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Parc Taulí, 1, Sabadell, 08208, Barcelona, Spain.
Introduction: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition associated with considerable pain and impaired health-related quality of life (HRQoL) for affected patients. Despite the documented increase in healthcare resource utilization (HRU) related to axSpA, few studies have explored the impact of diagnostic delays on these outcomes. This study sought to determine the association between diagnostic delay of axial spondyloarthritis (axSpA) and costs in the 3 years after diagnosis.
View Article and Find Full Text PDFGenetics of Prader-Willi and Angelman syndromes: 2024 update.
Curr Opin Psychiatry
December 2024
Departments of Psychiatry &, Behavioral Sciences and Pediatrics, University of Kansas Medical Centre, Kansas City, Kansas, United States.
Purpose Of Review: Prader-Willi (PWS) and Angelman (AS) syndromes arise from errors in 15q11-q13 imprinting. This review describes recent advances in genomics and how these expand our understanding of these rare disorders, guiding treatment strategies to improve patient outcomes.
Recent Findings: PWS features include severe infantile hypotonia, failure to thrive, hypogonadism, developmental delay, behavioral and psychiatric features, hyperphagia, and morbid obesity, if unmanaged.
From biological marker to clinical application: the role of anti-Müllerian hormone (AMH) for delayed puberty and idiopathic non-obstructive azoospermia in males.
Endocr Connect
January 2025
X Jiang, Human Sperm Bank, Sichuan University West China Second University Hospital, Chengdu, China.
Anti-Müllerian hormone (AMH), a biomarker secreted by Sertoli cells in the testes, has emerged as a critical indicator of male reproductive function with significant clinical application potential. AMH reflects Sertoli cell activity and plays a pivotal role across different stages of male gonadal function. Firstly, in prepubertal males, AMH levels are crucial for assessing testicular development and the progression of puberty, with delayed or insufficient AMH secretion often being associated with disorders like delayed puberty.
View Article and Find Full Text PDFBeyond Dermatological Findings: Multisystem Involvement in Prolidase Deficiency.
Turk Arch Pediatr
January 2025
Division of Allergy and Immunology, Department of Pediatrics, Marmara University Faculty of Medicine, İstanbul, Türkiye.
Objective: Prolidase deficiency is a metabolic and immunological disorder that is inherited in an autosomal recessive manner. In prolidase deficiency, a broad spectrum of differences is observed in patients, ranging from asymptomatic to multisystem involvement. There is scarce information in the literature on the atypical features and immunophenotypes of this disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!